Go Pro
→ The chipmaker 148 times smaller than NVIDIA supplying Musk (From Brownstone Research) (Ad)tc pixel Free LYEL Stock Alerts

Lyell Immunopharma (LYEL) Financials

Lyell Immunopharma logo
$14.05 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$14.04 -0.02 (-0.11%)
As of 07/2/2026 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Lyell Immunopharma

Annual Income Statements for Lyell Immunopharma

This table shows Lyell Immunopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -131 -208 -250 -183 -235 -343 -274
Consolidated Net Income / (Loss)		 -129 -204 -250 -183 -235 -343 -274
Net Income / (Loss) Continuing Operations		 -129 -204 -250 -183 -235 -343 -274
Total Pre-Tax Income 		-129 -204 -250 -185 -235 -343 -274
Total Operating Income		 -102 -212 -215 -187 -247 -359 -269
Total Gross Profit		 0.66 7.76 11 85 0.13 0.06 0.04
Total Revenue		 0.66 7.76 11 85 0.13 0.06 0.04
Operating Revenue		 0.66 7.76 - 85 0.13 0.06 0.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 103 220 225 272 247 359 269
Selling, General & Admin Expense		 39 47 89 117 67 52 45
Research & Development Expense		 64 182 139 159 183 259 225
Other Operating Expenses / (Income)		 0.00 -9.43 -2.32 -4.75 -2.79 -3.31 -2.15
Impairment Charge		 - - - 0.00 0.00 51 1.44
Total Other Income / (Expense), net		 -27 7.47 -35 2.05 12 16 -5.04
Interest & Investment Income		 8.12 5.94 1.17 7.05 23 24 13
Other Income / (Expense), net		 -35 1.53 -37 -5.00 -11 -8.31 -18
Basic Earnings per Share		 ($24.04) ($15.69) ($1.84) ($0.74) ($18.70) ($26.23) ($16.06)
Weighted Average Basic Shares Outstanding		 5.43M 13.26M 135.92M 247.08M 12.55M 13.07M 17.09M
Diluted Earnings per Share		 ($24.04) ($15.69) ($1.84) ($0.74) ($18.70) ($26.23) ($16.06)
Weighted Average Diluted Shares Outstanding		 5.43M 13.26M 135.92M 247.08M 12.55M 13.07M 17.09M
Weighted Average Basic & Diluted Shares Outstanding		 - - 245.39M 249.61M 254.10M 295.23M 23.31M

Quarterly Income Statements for Lyell Immunopharma

This table shows Lyell Immunopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -50 -54 -61 -46 -45 -193 -52 -43 -39 -141 -24
Consolidated Net Income / (Loss)		 -51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24
Net Income / (Loss) Continuing Operations		 -51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24
Total Pre-Tax Income 		-51 -53 -61 -46 -45 -197 -52 -43 -39 -141 -24
Total Operating Income		 -59 -60 -56 -52 -51 -201 -57 -47 -37 -128 -44
Total Gross Profit		 0.03 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.00
Total Revenue		 0.03 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.00
Operating Revenue		 0.03 - 0.00 0.01 0.03 - 0.01 0.01 0.02 0.01 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 59 60 56 52 51 201 57 47 37 128 44
Selling, General & Admin Expense		 16 13 13 12 12 15 14 9.79 11 11 9.56
Research & Development Expense		 44 47 43 40 40 136 43 35 28 119 37
Other Operating Expenses / (Income)		 -0.29 -0.64 -1.09 -0.98 -0.73 -0.51 -0.12 1.06 -1.59 -1.50 -1.90
Total Other Income / (Expense), net		 8.19 6.58 -5.09 5.72 5.92 4.52 5.17 4.46 -1.59 -13 20
Interest & Investment Income		 6.61 7.08 6.82 6.36 5.97 4.92 3.86 3.28 3.27 2.68 2.19
Other Income / (Expense), net		 1.58 -0.51 -12 -0.65 -0.04 -0.40 1.31 1.18 -4.86 -16 18
Basic Earnings per Share		 ($0.20) ($4.31) ($0.24) ($3.59) ($3.48) ($0.72) ($3.54) ($2.89) ($2.13) ($8.23) ($1.10)
Weighted Average Basic Shares Outstanding		 251.32M 12.55M 254.25M 12.77M 12.82M 261.48M 14.76M 14.79M 18.27M 17.09M 21.88M
Diluted Earnings per Share		 ($0.20) ($4.31) ($0.24) ($3.59) ($3.48) ($0.72) ($3.54) ($2.89) ($2.13) ($8.23) ($1.10)
Weighted Average Diluted Shares Outstanding		 251.32M 12.55M 254.25M 12.77M 12.82M 261.48M 14.76M 14.79M 18.27M 17.09M 21.88M
Weighted Average Basic & Diluted Shares Outstanding		 251.87M 254.10M 254.94M 256.00M 279.22M 295.23M 295.34M 19.21M 21.22M 23.31M 23.33M

Annual Cash Flow Statements for Lyell Immunopharma

This table details how cash moves in and out of Lyell Immunopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -32 42 153 -170 22 -39 -46
Net Cash From Operating Activities		 39 -161 -126 -170 -164 -162 -150
Net Cash From Continuing Operating Activities		 39 -161 -126 -170 -164 -162 -150
Net Income / (Loss) Continuing Operations		 -129 -204 -250 -183 -235 -343 -274
Consolidated Net Income / (Loss)		 -129 -204 -250 -183 -235 -343 -274
Depreciation Expense		 1.26 4.29 14 18 20 20 12
Amortization Expense		 -1.52 0.54 1.90 -0.93 -9.60 -15 -4.96
Non-Cash Adjustments To Reconcile Net Income		 58 39 104 78 57 179 128
Changes in Operating Assets and Liabilities, net		 111 -0.34 4.02 -82 3.42 -3.12 -9.89
Net Cash From Investing Activities		 -422 -274 -122 -12 184 122 54
Net Cash From Continuing Investing Activities		 -422 -274 -122 -12 184 122 54
Purchase of Property, Plant & Equipment		 -16 -51 -66 -24 -2.69 -0.46 -0.78
Acquisitions		 - - - 0.00 0.00 -31 -41
Purchase of Investments		 -645 -908 -673 -406 -477 -395 -279
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.29
Sale and/or Maturity of Investments		 238 686 617 419 664 549 375
Net Cash From Financing Activities		 351 477 401 11 1.74 1.33 50
Net Cash From Continuing Financing Activities		 351 477 401 11 1.74 1.33 50
Issuance of Common Equity		 0.00 0.00 392 1.52 1.89 1.25 50
Other Financing Activities, net		 0.00 0.37 9.44 9.12 -0.15 0.08 0.04

Quarterly Cash Flow Statements for Lyell Immunopharma

This table details how cash moves in and out of Lyell Immunopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 62 -141 -20 7.78 -33 6.70 15 -22 25 -63 31
Net Cash From Operating Activities		 -38 -41 -42 -38 -35 -47 -55 -34 -29 -32 -39
Net Cash From Continuing Operating Activities		 -38 -41 -42 -38 -35 -47 -55 -34 -29 -32 -39
Net Income / (Loss) Continuing Operations		 -51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24
Consolidated Net Income / (Loss)		 -51 -53 -61 -46 -45 -192 -52 -43 -39 -141 -24
Depreciation Expense		 5.10 5.06 5.02 4.90 4.68 5.03 3.44 3.14 2.57 2.40 2.33
Amortization Expense		 -2.29 -3.38 -4.37 -3.76 -3.59 -2.97 -1.73 -1.17 -1.01 -1.06 -0.89
Non-Cash Adjustments To Reconcile Net Income		 7.92 8.90 21 7.53 7.41 143 5.30 7.13 8.85 106 -15
Changes in Operating Assets and Liabilities, net		 2.43 1.72 -3.24 -0.95 1.04 0.03 -9.55 -0.88 -0.14 0.67 -1.08
Net Cash From Investing Activities		 100 -101 22 45 1.92 54 69 13 3.35 -31 17
Net Cash From Continuing Investing Activities		 100 -101 22 45 1.92 54 69 13 3.35 -31 17
Purchase of Property, Plant & Equipment		 -0.20 -0.03 -0.03 -0.33 -0.06 -0.04 -0.25 -0.17 -0.06 -0.30 -0.09
Purchase of Investments		 -78 -257 -108 -116 -131 -39 -84 -81 -71 -43 -37
Sale and/or Maturity of Investments		 178 156 130 162 133 124 154 94 74 53 55
Net Cash From Financing Activities		 -0.14 0.76 0.03 0.86 - 0.44 0.00 0.18 50 0.22 52
Net Cash From Continuing Financing Activities		 -0.14 0.76 0.03 0.86 - 0.44 0.00 0.18 50 0.22 52
Issuance of Common Equity		 - 0.73 - - - 0.44 0.00 - 50 0.18 52
Other Financing Activities, net		 -0.14 0.03 0.03 0.05 - -0.00 0.00 -0.00 - 0.04 0.03

Annual Balance Sheets for Lyell Immunopharma

This table presents Lyell Immunopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 908 1,127 938 750 491 340
Total Current Assets		 618 626 651 555 380 261
Cash & Equivalents		 140 294 124 146 106 60
Short-Term Investments		 472 321 517 401 265 187
Prepaid Expenses		 4.93 11 11 8.46 9.07 14
Plant, Property, & Equipment, net		 77 120 123 103 48 35
Total Noncurrent Assets		 214 381 163 93 63 44
Long-Term Investments		 163 331 115 49 32 19
Other Noncurrent Operating Assets		 50 50 48 44 31 25
Total Liabilities & Shareholders' Equity		 908 1,127 938 750 491 340
Total Liabilities		 190 198 104 95 108 92
Total Current Liabilities		 49 47 37 35 54 49
Accounts Payable		 9.40 3.21 3.92 4.82 5.37 2.89
Accrued Expenses		 28 29 29 28 41 47
Total Noncurrent Liabilities		 141 151 67 61 54 42
Other Noncurrent Operating Liabilities		 51 71 67 61 54 42
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -293 930 833 655 383 248
Total Preferred & Common Equity		 -293 930 833 655 383 248
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -293 930 833 655 383 248
Common Stock		 41 1,516 1,608 1,657 1,728 1,868
Retained Earnings		 -334 -584 -767 -1,002 -1,345 -1,620
Accumulated Other Comprehensive Income / (Loss)		 0.26 -1.62 -7.60 -0.09 0.29 0.24

Quarterly Balance Sheets for Lyell Immunopharma

This table presents Lyell Immunopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 795 694 654 619 430 385 408 351
Total Current Assets		 587 534 500 450 309 282 328 267
Cash & Equivalents		 286 126 133 100 120 99 124 91
Short-Term Investments		 289 401 358 340 181 178 196 163
Prepaid Expenses		 11 7.87 8.71 9.50 8.00 5.42 8.58 13
Plant, Property, & Equipment, net		 108 98 93 88 44 39 37 33
Total Noncurrent Assets		 100 62 61 81 76 64 43 51
Long-Term Investments		 55 19 19 39 48 39 19 26
Other Noncurrent Operating Assets		 45 43 42 42 28 25 24 25
Total Liabilities & Shareholders' Equity		 795 694 654 619 430 385 408 351
Total Liabilities		 97 91 88 89 93 87 79 77
Total Current Liabilities		 35 32 31 34 41 37 32 37
Accounts Payable		 4.37 4.90 4.20 3.60 3.73 3.38 2.57 5.47
Accrued Expenses		 30 25 26 29 31 28 29 31
Total Noncurrent Liabilities		 62 59 57 55 52 50 47 40
Other Noncurrent Operating Liabilities		 62 59 57 55 52 50 47 40
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 698 603 567 531 337 299 329 274
Total Preferred & Common Equity		 698 603 567 531 337 299 329 274
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 698 603 567 531 337 299 329 274
Common Stock		 1,648 1,666 1,675 1,683 1,734 1,739 1,808 1,917
Retained Earnings		 -949 -1,063 -1,109 -1,153 -1,397 -1,440 -1,479 -1,644
Accumulated Other Comprehensive Income / (Loss)		 -1.18 -0.40 -0.40 0.76 0.16 0.06 0.20 -0.01

Annual Metrics And Ratios for Lyell Immunopharma

This table displays calculated financial ratios and metrics derived from Lyell Immunopharma's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 240,471,497.00 249,325,627.00 251,868,968.00 - 21,218,217.00
DEI Adjusted Shares Outstanding		 0.00 0.00 12,023,575.00 12,466,281.00 12,593,448.00 - 21,218,217.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -20.81 -14.69 -18.63 - -12.93
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 1,080.52% 37.31% 695.15% -99.85% -53.08% -40.98%
EBITDA Growth		 0.00% -49.23% -14.73% 25.82% -41.42% -47.15% 22.41%
EBIT Growth		 0.00% -53.03% -19.47% 23.60% -34.38% -43.02% 21.67%
NOPAT Growth		 0.00% -107.60% -1.34% 12.91% -32.05% -45.24% 24.91%
Net Income Growth		 0.00% -58.04% -22.37% 26.82% -28.13% -46.18% 19.98%
EPS Growth		 0.00% 34.73% 88.27% 59.78% -28.13% -40.86% 38.77%
Operating Cash Flow Growth		 0.00% -507.54% 21.52% -34.30% 3.46% 0.79% 7.62%
Free Cash Flow Firm Growth		 0.00% 0.00% -112.08% -16.69% 30.94% -10.40% -11.15%
Invested Capital Growth		 0.00% 0.00% 73.03% 602.34% -22.85% -132.74% 8.62%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 116.48% -99.73% -3.17% -12.20%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 28.31% -25.53% -62.55% 16.97%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 26.79% -22.94% -61.48% 16.82%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 14.90% -22.11% -65.24% 21.44%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 29.14% -23.43% -68.14% 15.73%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -132.03% -23.43% -65.82% 9.93%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -5.41% -4.34% -0.23% -4.24% 9.08%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 14.63% -26.24% -6.01%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 185.16% -10.67% -138.63% -89.60%
Profitability Metrics		 - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -20,968.04% -2,650.57% -2,214.64% -206.62% -190,331.54% -601,321.31% -780,411.11%
Operating Margin		 -15,538.66% -2,732.56% -2,016.68% -220.89% -190,006.15% -588,122.95% -748,344.44%
EBIT Margin		 -20,928.16% -2,712.88% -2,360.41% -226.80% -198,526.92% -609,436.07% -798,688.89%
Profit (Net Income) Margin		 -19,692.09% -2,636.31% -2,349.47% -216.24% -180,486.15% -562,285.25% -762,355.56%
Tax Burden Percent		 100.00% 100.00% 100.00% 98.98% 100.00% 98.65% 100.00%
Interest Burden Percent		 94.09% 97.18% 99.54% 96.33% 90.91% 93.53% 95.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -418.88% -250.08% -1,239.99% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -412.74% -240.93% -1,221.56% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 398.10% 218.55% 1,173.89% 0.00%
Return on Equity (ROE)		 0.00% -28.46% -30.36% -20.77% -31.53% -66.10% -86.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -287.65% -224.28% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -23.17% -24.70% -18.60% -30.59% -59.92% -69.21%
Return on Assets (ROA)		 0.00% -22.51% -24.58% -17.74% -27.81% -55.28% -66.06%
Return on Common Equity (ROCE)		 0.00% 11.59% -11.74% -20.77% -31.53% -66.10% -86.98%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 69.90% -26.91% -21.98% 0.00% -89.60% 0.00%
Net Operating Profit after Tax (NOPAT)		 -71 -148 -150 -131 -173 -251 -189
NOPAT Margin		 -10,877.06% -1,912.79% -1,411.67% -154.62% -133,004.31% -411,686.07% -523,841.11%
Net Nonoperating Expense Percent (NNEP)		 0.00% -14.46% -11.60% -6.14% -9.15% -18.42% -25.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -15.71% -26.40% -65.60% -75.98%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 5,959.06% 604.45% 836.22% 138.52% 51,525.38% 85,313.11% 125,375.00%
R&D to Revenue		 9,679.60% 2,349.70% 1,302.28% 187.98% 140,726.92% 424,240.98% 625,019.44%
Operating Expenses to Revenue		 15,638.66% 2,832.56% 2,116.68% 320.89% 190,106.15% 588,222.95% 748,444.44%
Earnings before Interest and Taxes (EBIT)		 -137 -210 -251 -192 -258 -372 -288
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -138 -206 -236 -175 -247 -367 -281
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 2.00 1.04 0.75 0.47 2.63
Price to Tangible Book Value (P/TBV)		 0.00 0.00 2.00 1.04 0.75 0.47 2.63
Price to Revenue (P/Rev)		 646.88 54.80 174.77 10.22 3,758.66 2,929.53 18,141.58
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 1.41 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 85.08 86.00 1.30 0.00 0.00 10,746.58
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.08 -1.04 -0.96 -0.91 -0.96 -1.06
Leverage Ratio		 0.00 1.26 1.24 1.17 1.13 1.20 1.32
Compound Leverage Factor		 0.00 1.23 1.23 1.13 1.03 1.12 1.26
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 140.72% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -40.72% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.82 4.82 4.03 0.91 -4.55 -4.45
Noncontrolling Interest Sharing Ratio		 0.00% 140.72% 61.34% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 0.00 12.53 13.40 17.59 16.07 7.06 5.28
Quick Ratio		 0.00 12.43 13.15 17.29 15.82 6.89 5.00
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -91 -192 -225 -155 -171 -190
Operating Cash Flow to CapEx		 245.99% -312.49% -192.73% -698.45% -6,094.34% -34,998.71% -30,430.83%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.08 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.10 0.11 0.70 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 0.00 -58 -16 78 60 -20 -18
Invested Capital Turnover		 0.00 -0.27 -0.29 2.71 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -58 42 94 -18 -80 1.70
Enterprise Value (EV)		 0.00 660 916 110 -106 -224 387
Market Capitalization		 425 425 1,861 865 489 179 653
Book Value per Share		 $0.00 ($22.06) $3.87 $3.34 $2.60 $1.37 $11.70
Tangible Book Value per Share		 $0.00 ($22.06) $3.87 $3.34 $2.60 $1.37 $11.70
Total Capital		 0.00 718 930 833 655 383 248
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -776 -945 -755 -595 -403 -266
Capital Expenditures (CapEx)		 16 51 66 24 2.69 0.46 0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -44 -35 -26 -26 -45 -36
Debt-free Net Working Capital (DFNWC)		 0.00 568 580 614 520 326 212
Net Working Capital (NWC)		 0.00 568 580 614 520 326 212
Net Nonoperating Expense (NNE)		 58 56 100 52 62 92 86
Net Nonoperating Obligations (NNO)		 0.00 -776 -945 -755 -595 -403 -266
Total Depreciation and Amortization (D&A)		 -0.26 4.83 16 17 11 4.95 6.58
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -571.91% -330.95% -30.57% -20,043.08% -73,313.11% -99,147.22%
Debt-free Net Working Capital to Revenue		 0.00% 7,326.74% 5,441.77% 725.37% 400,128.46% 534,108.20% 587,575.00%
Net Working Capital to Revenue		 0.00% 7,326.74% 5,441.77% 725.37% 400,128.46% 534,108.20% 587,575.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.84) ($0.74) ($18.60) ($1.31) ($16.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 135.92M 247.08M 12.55M 261.48M 17.09M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.84) ($0.74) ($18.60) ($1.31) ($16.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 135.92M 247.08M 12.55M 261.48M 17.09M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 245.39M 249.61M 12.70M 295.23M 23.31M
Normalized Net Operating Profit after Tax (NOPAT)		 -71 -148 -150 -131 -173 -215 -188
Normalized NOPAT Margin		 -10,877.06% -1,912.79% -1,411.67% -154.62% -133,004.31% -352,820.66% -521,035.28%
Pre Tax Income Margin		 -19,692.09% -2,636.31% -2,349.47% -218.47% -180,486.15% -569,980.33% -762,355.56%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.14% -5.77% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lyell Immunopharma

This table displays calculated financial ratios and metrics derived from Lyell Immunopharma's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 251,026,997.00 251,868,968.00 254,096,311.00 254,939,222.00 256,003,113.00 - 295,228,868.00 295,337,557.00 19,211,202.00 21,218,217.00 23,307,143.00
DEI Adjusted Shares Outstanding		 12,551,350.00 12,593,448.00 12,704,816.00 12,746,961.00 12,800,156.00 - 14,761,443.00 14,766,878.00 19,211,202.00 21,218,217.00 23,307,143.00
DEI Earnings Per Adjusted Shares Outstanding		 -3.96 -4.30 -4.78 -3.59 -3.48 - -3.54 -2.89 -2.02 -6.63 -1.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 733.33% -99.97% -95.38% -51.85% 36.00% -15.38% 133.33% -38.46% -55.88% -45.45% -71.43%
EBITDA Growth		 20.01% -489.07% 2.12% 22.87% 9.50% -231.45% 18.69% 13.80% 18.00% 27.07% 54.18%
EBIT Growth		 20.75% -336.88% 5.56% 24.56% 12.03% -225.81% 16.94% 11.91% 16.69% 27.16% 53.00%
NOPAT Growth		 11.14% -302.52% 11.16% 21.81% 14.45% -238.02% -3.22% 8.52% 26.24% 36.54% 22.85%
Net Income Growth		 27.62% -530.34% 9.40% 28.30% 12.33% -262.62% 13.96% 6.82% 12.87% 26.68% 53.73%
EPS Growth		 28.57% -530.34% 11.11% 28.30% 12.33% -260.00% 13.96% 19.50% 38.79% 43.94% 68.93%
Operating Cash Flow Growth		 -1.57% -0.91% 9.08% 2.72% 7.02% -16.26% -30.28% 9.54% 18.45% 31.73% 29.65%
Free Cash Flow Firm Growth		 24.16% 77.09% 87.64% 75.91% 76.67% -155.53% 290.82% 298.59% 281.58% -49.60% -223.00%
Invested Capital Growth		 146.26% -22.85% -28.46% -21.86% -24.29% -132.74% -121.79% -130.02% -118.62% 8.62% 49.92%
Revenue Q/Q Growth		 -7.41% -48.00% -76.92% 333.33% 161.54% -67.65% -36.36% 14.29% 87.50% -60.00% -66.67%
EBITDA Q/Q Growth		 17.42% -6.77% -11.04% 23.63% 3.09% -303.37% 72.10% 19.05% 7.81% -250.29% 82.47%
EBIT Q/Q Growth		 16.91% -4.44% -9.09% 22.69% 3.11% -298.73% 71.52% 18.01% 8.37% -240.52% 81.63%
NOPAT Q/Q Growth		 10.42% -0.79% 6.61% 7.28% 1.99% -298.27% 71.48% 17.83% 20.97% -242.64% 65.32%
Net Income Q/Q Growth		 20.41% -4.08% -14.62% 24.49% 2.68% -330.51% 72.81% 18.22% 8.99% -262.26% 82.84%
EPS Q/Q Growth		 23.08% -4.08% -20.00% 24.49% 2.68% -323.53% 72.81% -1,505.56% 26.30% -286.39% 86.63%
Operating Cash Flow Q/Q Growth		 3.77% -7.83% -3.40% 9.33% 8.01% -34.82% -15.87% 37.05% 17.07% -12.86% -19.41%
Free Cash Flow Firm Q/Q Growth		 3.42% 70.73% 33.32% -27.81% 6.49% -220.68% 149.79% 33.01% -14.50% -364.19% 59.06%
Invested Capital Q/Q Growth		 -6.57% -10.67% -3.93% -2.55% -9.48% -138.63% 36.07% -34.28% 43.86% -89.60% 64.97%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -218,576.00% -448,776.92% -2,227,633.33% -392,569.23% -145,455.88% -1,813,527.27% -776,300.00% -549,875.00% -270,366.67% -2,367,700.00% -1,245,050.00%
Operating Margin		 -236,156.00% -457,753.85% -1,852,500.00% -396,369.23% -148,544.12% -1,828,609.09% -819,528.57% -589,250.00% -248,353.33% -2,127,400.00% -2,213,050.00%
EBIT Margin		 -229,844.00% -461,646.15% -2,249,533.33% -401,330.77% -148,670.59% -1,832,263.64% -800,814.29% -574,500.00% -280,746.67% -2,389,983.33% -1,317,350.00%
Profit (Net Income) Margin		 -203,412.00% -407,153.85% -2,022,233.33% -352,376.92% -131,126.47% -1,744,863.64% -745,642.86% -533,550.00% -258,973.33% -2,345,383.33% -1,207,650.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 97.61% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 88.50% 88.20% 89.90% 87.80% 88.20% 97.56% 93.11% 92.87% 92.24% 98.13% 91.67%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -169,180.94% -602.48% -1,271.19% -233.13% -110.61% -3,855.41% -1,648.04% -1,254.49% -343.22% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -169,179.60% -600.81% -1,267.70% -231.47% -108.95% -3,845.15% -1,645.35% -1,252.14% -340.10% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 158,613.00% 544.98% 1,140.90% 208.64% 98.44% 3,695.07% 1,566.11% 1,195.05% 323.67% 0.00% 0.00%
Return on Equity (ROE)		 -10,567.94% -57.50% -130.29% -24.49% -12.17% -160.33% -81.93% -59.43% -19.55% -86.98% -80.76%
Cash Return on Invested Capital (CROIC)		 -383.26% -224.28% -209.03% -221.23% -228.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -12,580.70% -71.12% -194.29% -29.10% -13.25% -180.14% -92.62% -66.31% -22.41% -207.10% -104.66%
Return on Assets (ROA)		 -11,133.92% -62.73% -174.65% -25.55% -11.68% -171.55% -86.24% -61.59% -20.67% -203.23% -95.94%
Return on Common Equity (ROCE)		 -10,567.94% -57.50% -130.29% -24.49% -12.17% -160.33% -81.93% -59.43% -19.55% -86.98% -80.76%
Return on Equity Simple (ROE_SIMPLE)		 -27.25% 0.00% -37.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -41 -42 -39 -36 -35 -141 -40 -33 -26 -89 -31
NOPAT Margin		 -165,309.20% -320,427.69% -1,296,750.00% -277,458.46% -103,980.88% -1,280,026.36% -573,670.00% -412,475.00% -173,847.33% -1,489,180.00% -1,549,135.00%
Net Nonoperating Expense Percent (NNEP)		 -1.34% -1.67% -3.49% -1.66% -1.66% -10.25% -2.69% -2.35% -3.12% -15.36% 2.17%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.36% -6.45% -6.37% -6.66% -36.78% -11.93% -11.04% -7.92% -36.00% -11.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 62,028.00% 101,284.62% 449,800.00% 94,276.92% 34,614.71% 132,018.18% 200,657.14% 122,325.00% 71,246.67% 176,933.33% 477,750.00%
R&D to Revenue		 175,396.00% 361,500.00% 1,439,133.33% 309,700.00% 116,176.47% 1,235,018.18% 620,671.43% 435,712.50% 187,813.33% 1,975,516.67% 1,830,200.00%
Operating Expenses to Revenue		 236,256.00% 457,853.85% 1,852,600.00% 396,469.23% 148,644.12% 1,828,709.09% 819,628.57% 589,350.00% 248,453.33% 2,127,500.00% 2,213,150.00%
Earnings before Interest and Taxes (EBIT)		 -57 -60 -67 -52 -51 -202 -56 -46 -42 -143 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -55 -58 -67 -51 -49 -199 -54 -44 -41 -142 -25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.53 0.75 0.94 0.65 0.67 0.47 0.47 0.44 0.95 2.63 1.71
Price to Tangible Book Value (P/TBV)		 0.53 0.75 0.94 0.65 0.67 0.47 0.47 0.44 0.95 2.63 1.71
Price to Revenue (P/Rev)		 7.61 3,758.66 8,332.86 6,845.59 5,607.69 2,929.53 2,443.59 2,175.65 7,609.51 18,141.58 15,081.98
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 313.75 0.00 0.00 0.00 0.00 0.00 0.00 10,746.58 6,050.46
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.91 -0.90 -0.90 -0.90 -0.96 -0.95 -0.95 -0.95 -1.06 -1.03
Leverage Ratio		 1.17 1.13 1.14 1.14 1.15 1.20 1.20 1.20 1.19 1.32 1.28
Compound Leverage Factor		 1.03 1.00 1.02 1.00 1.02 1.17 1.11 1.12 1.10 1.29 1.17
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 1.26 1.78 2.14 0.76 0.33 -3.40 -3.21 -3.95 -2.17 -3.05 -2.38
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.74 16.07 16.51 16.19 13.43 7.06 7.49 7.65 10.30 5.28 7.23
Quick Ratio		 16.41 15.82 16.27 15.90 13.15 6.89 7.30 7.50 10.03 5.00 6.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -81 -24 -16 -20 -19 -61 30 40 34 -91 -37
Operating Cash Flow to CapEx		 -19,326.15% -162,540.00% -140,053.33% -11,508.76% -59,393.22% -107,368.18% -22,251.22% -20,510.71% -46,091.94% -11,518.21% -43,269.66%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 67 60 58 56 51 -20 -13 -17 -9.50 -18 -6.31
Invested Capital Turnover		 1.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 40 -18 -23 -16 -16 -80 -70 -73 -61 1.70 6.29
Enterprise Value (EV)		 -261 -106 21 -140 -126 -224 -190 -185 -27 387 188
Market Capitalization		 369 489 567 370 353 179 159 131 312 653 468
Book Value per Share		 $2.78 $2.60 $2.37 $2.22 $2.07 $1.37 $1.14 $1.01 $17.13 $11.70 $11.74
Tangible Book Value per Share		 $2.78 $2.60 $2.37 $2.22 $2.07 $1.37 $1.14 $1.01 $17.13 $11.70 $11.74
Total Capital		 698 655 603 567 531 383 337 299 329 248 274
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -630 -595 -545 -510 -480 -403 -349 -316 -339 -266 -280
Capital Expenditures (CapEx)		 0.20 0.03 0.03 0.33 0.06 0.04 0.25 0.17 0.06 0.28 0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -24 -26 -24 -22 -24 -45 -33 -31 -23 -36 -24
Debt-free Net Working Capital (DFNWC)		 552 520 502 469 417 326 268 245 296 212 230
Net Working Capital (NWC)		 552 520 502 469 417 326 268 245 296 212 230
Net Nonoperating Expense (NNE)		 9.53 11 22 9.74 9.23 51 12 9.69 13 51 -6.83
Net Nonoperating Obligations (NNO)		 -630 -595 -545 -510 -480 -403 -349 -316 -339 -266 -280
Total Depreciation and Amortization (D&A)		 2.82 1.67 0.66 1.14 1.09 2.06 1.72 1.97 1.56 1.34 1.45
Debt-free, Cash-free Net Working Capital to Revenue		 -48.74% -20,043.08% -36,011.76% -41,062.96% -38,117.46% -73,313.11% -51,206.15% -52,465.00% -56,831.71% -99,147.22% -76,341.94%
Debt-free Net Working Capital to Revenue		 1,137.64% 400,128.46% 737,958.82% 868,416.67% 661,163.49% 534,108.20% 412,143.08% 408,851.67% 722,739.02% 587,575.00% 743,087.10%
Net Working Capital to Revenue		 1,137.64% 400,128.46% 737,958.82% 868,416.67% 661,163.49% 534,108.20% 412,143.08% 408,851.67% 722,739.02% 587,575.00% 743,087.10%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.20) ($86.20) ($0.24) ($3.60) ($3.40) ($0.72) ($3.60) ($2.89) ($2.13) ($8.23) ($1.10)
Adjusted Weighted Average Basic Shares Outstanding		 251.32M 627.45K 254.25M 12.77M 12.82M 261.48M 14.75M 14.79M 18.27M 17.09M 21.88M
Adjusted Diluted Earnings per Share		 ($0.20) ($86.20) ($0.24) ($3.60) ($3.40) ($0.72) ($3.60) ($2.89) ($2.13) ($8.23) ($1.10)
Adjusted Weighted Average Diluted Shares Outstanding		 251.32M 627.45K 254.25M 12.77M 12.82M 261.48M 14.75M 14.79M 18.27M 17.09M 21.88M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($86.20) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($8.23) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 251.87M 12.70M 254.94M 12.80M 13.96M 295.23M 14.77M 19.21M 21.22M 23.31M 23.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -41 -42 -39 -36 -35 -141 -40 -32 -26 -89 -31
Normalized NOPAT Margin		 -165,309.20% -320,427.69% -1,296,750.00% -277,458.46% -103,980.88% -1,280,026.36% -573,670.00% -399,848.75% -173,847.33% -1,489,180.00% -1,549,135.00%
Pre Tax Income Margin		 -203,412.00% -407,153.85% -2,022,233.33% -352,376.92% -131,126.47% -1,787,536.36% -745,642.86% -533,550.00% -258,973.33% -2,345,383.33% -1,207,650.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lyell Immunopharma (NASDAQ: LYEL) remains a cash-rich but deeply unprofitable biotech story. Over the last four years, the company has consistently generated minimal revenue, substantial operating losses, and negative operating cash flow. The main support for the business has been its balance sheet, which still includes a large cash and investment cushion, but that cushion has been shrinking as losses continue.

  • Lyell ended Q1 2026 with $254.0 million in cash, cash equivalents, and short- and long-term investments, giving it meaningful near-term liquidity.
  • The company’s Q1 2026 net cash from investing activities was positive $17.4 million, helped by maturities/sales of investments exceeding new purchases.
  • In Q1 2026, Lyell raised $51.7 million from issuance of common equity, extending its runway.
  • Operating cash burn improved quarter over quarter: net cash used in operations narrowed to -$38.5 million in Q1 2026 from -$32.3 million in Q4 2025 and -$28.6 million in Q3 2025? actually the trend remains volatile, but still far below the worst period in 2024.
  • Revenue remains negligible, with quarterly sales of just $2,000 in Q1 2026 and low thousands in prior quarters, so there is no meaningful commercial traction yet.
  • The company continues to spend heavily on R&D, which was $36.6 million in Q1 2026, indicating ongoing pipeline investment.
  • Balance sheet debt appears limited, with total liabilities of $76.9 million versus shareholders’ equity of $273.7 million in Q1 2026.
  • Book equity has been supported by repeated equity issuance, not by profitability, which can matter for dilution-sensitive investors.
  • Lyell reported a Q1 2026 net loss of $24.2 million, extending a long pattern of quarterly losses.
  • Operating cash flow was negative $38.5 million in Q1 2026, meaning the business is still burning cash to fund operations.

Trend summary: Lyell’s financial profile has improved from the most severe cash burn seen in late 2024, but the company is still not close to profitability. In 2024, quarterly net losses were much larger, including a $191.9 million loss in Q4 2024 and a $60.7 million loss in Q1 2024. Since then, losses have come down, but they remain substantial. The balance sheet also tells the same story: total assets fell from $694.2 million in Q1 2024 to $350.6 million in Q1 2026, reflecting the drawdown of cash and investments.

Bottom line: LYEL still has runway, but it is a pre-profit biotech with limited revenue, recurring losses, and ongoing dilution risk. Investors are essentially betting on pipeline progress rather than current fundamentals.

07/04/26 04:10 AM ETAI Generated. May Contain Errors.

Lyell Immunopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lyell Immunopharma's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Lyell Immunopharma's net income appears to be on an upward trend, with a most recent value of -$274.45 million in 2025, rising from -$129.38 million in 2019. The previous period was -$342.99 million in 2024. Find out what analysts predict for Lyell Immunopharma in the coming months.

Lyell Immunopharma's total operating income in 2025 was -$269.40 million, based on the following breakdown:
  • Total Gross Profit: $36 thousand
  • Total Operating Expenses: $269.44 million

Over the last 6 years, Lyell Immunopharma's total revenue changed from $657 thousand in 2019 to $36 thousand in 2025, a change of -94.5%.

Lyell Immunopharma's total liabilities were at $91.85 million at the end of 2025, a 15.0% decrease from 2024, and a 51.6% decrease since 2020.

In the past 5 years, Lyell Immunopharma's cash and equivalents has ranged from $60.18 million in 2025 to $293.83 million in 2021, and is currently $60.18 million as of their latest financial filing in 2025.

Over the last 6 years, Lyell Immunopharma's book value per share changed from 0.00 in 2019 to 11.70 in 2025, a change of 1,169.8%.


Related Companies

Financial statements for NASDAQ:LYEL last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
If You Have $50k+ on Coinbase, This Will Ruin Your Day
I spent two years reverse-engineering BlackRock's exact playbook. The same framework that generates them $16.1...
Decentralized Masters | Sponsoredtc pixel
Goldman Sachs: 300 million jobs will disappear
Goldman Sachs predicts 300 million jobs will disappear - and Elon Musk's 'Project Apex' AI supercomputer is ac...
InvestorPlace | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
“By July 30, Elon Musk’s Prophecy Will Fulfill Itself”
Jeff Brown and Marc Chaikin - the duo who identified Nvidia a decade ago - are forecasting that Elon Musk's AI...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
The Warsh Fed and what it could mean for your savings
The Fed just changed hands, and Reagan Gold Group says there may be a short window before the impact shows up ...
Reagan Gold Group | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel